Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration
Immuto Scientific has closed an oversubscribed $8 million Seed 2 financing round led by DYDX, with participation from WARF Ventures, Gravity Fund, and Great Oaks Venture Capital, among others, and entered a drug discovery collaboration with Daiichi Sankyo. The work centers on the company’s AI-enabled structural surfaceomics platform to identify disease-specific cell-surface targets in oncology and beyond.
Structural surfaceomics examines protein presence as well as conformational states in patient-derived and live-cell samples. Immuto terms these disease-linked features Surface Protein Conformations (SPCs)—structures often missed by traditional discovery methods. The platform integrates high-resolution structural proteomics, live-cell structural assessment, and AI analytics to map SPCs at scale and reveal disease-specific epitopes, with the goal of enabling first-in-class, highly selective therapies.
Headquartered in Madison, Wisconsin, with operations in Cambridge, Massachusetts, Immuto is advancing an oncology-focused pipeline and plans to extend the platform to immunology and inflammation.
The collaboration with Daiichi Sankyo Research Institute Boston will focus on discovering novel targets in solid tumors and developing antibodies against them. Daiichi Sankyo retains an option to license assets generated from the partnership. Financial terms of the agreement were not disclosed.
The company reports that it has already demonstrated target identification across multiple tumor types and is advancing its internal oncology pipeline toward IND-enabling studies. With additional resources from the financing, Immuto also plans to extend applications of the structural surfaceomics platform into immunology and inflammation.
We track updates like this weekly in Where Tech Meets Bio—our newsletter on startups, platforms, and deals at the intersection of biotech and digital.
Topic: AI in Bio
